CNBC May 25, 2024
Annika Kim Constantino, Ashley Capoot

Key Points

– Some analysts estimate that anti-obesity medications could grow into a $100 billion industry by the end of the decade.

– Companies including Calibrate, Ro and WeightWatchers are looking to capitalize on the GLP-1 boom by launching weight loss programs around medications like Ozempic and Wegovy.

– Medication shortages, spotty insurance coverage and counterfeits have created challenges for companies and consumers.

For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had become a grueling task. She’d tried five different programs in her life and never found lasting results.

Her luck started to change last year, when she saw a promotion on Instagram for the Ro Body Program, a new offering from online health startup Ro....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Pharma / Biotech, Technology
Telehealth arrests at a key time for the industry
AI Diagnoses, Mental Wellness, and Caregiver Support See Big Wins | StartUp Health Insights: Week of Jun 18, 2023
How technology can help solve America’s health care accessibility crisis
Healthcare Leaders Embrace Virtual Care and AI to Combat Staffing Crisis: Philips Future Health Index 2024
Healthcare leaders lean on tech to curb staff shortages: 10 things to know

Share This Article